UroGen Pharma Ltd.
As of Oct 22, 2026, UroGen Pharma is in Stage 3, the topping phase, now in its first week (since Oct 16, 2026). It closed at $35.15, 30.1% below its 52-week high and above its 200-day average, which is rising.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is URGN early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
URGN among Biotechnology51st of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …51 | URGN | Stage 3 · wk 1 | 94 | −15.6% |
UroGen Pharma: quick answers
What stage is UroGen Pharma in?
As of Oct 22, 2026, UroGen Pharma (URGN) is in Stage 3, the topping phase. It entered Stage 3 on Oct 16, 2026 and is in its first week there. What the four stages mean
Is UroGen Pharma in an uptrend?
Its uptrend has stalled. UroGen Pharma is in Stage 3, the topping phase that follows an advance. It trades 13.6% above its 200-day average, which is rising.
How far is UroGen Pharma from its 52-week high?
UroGen Pharma closed at $35.15 on Oct 22, 2026, 30.1% below its 52-week high of $50.29. Its 52-week low is $17.00.
How has UroGen Pharma performed over the past year?
As of Oct 22, 2026, UroGen Pharma is up 93.8% over the past year and up 54.8% so far in 2026.
Which sector and industry is UroGen Pharma in?
UroGen Pharma is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.